title: Cocaine abuse may influence the response to imatinib in CML patients.
authors.affiliation: Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Fabiana
authors.initials: F
authors.lastname: Gentilini
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001549:Benzamides; D003042:Cocaine / Q000009:adverse effects / Q000494:pharmacology*; D019970:Cocaine-Related Disorders / Q000150:complications / Q000201:enzymology*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004347:Drug Interactions; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D008658:Inactivation, Metabolic; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000150:complications / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013379:Substrate Specificity
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D065607:Cytochrome P-450 Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D003577:Cytochrome P-450 Enzyme System; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D003042:Cocaine; D006918:Hydroxyurea